|
The FDA today issued a final guidance titled "Pharmacogenomic Data
Submissions" to speed development of new medical products through the science of
pharmacogenomics.
Pharmacogenomics allows health care providers to identify sources of an individual's profile of drug response and predict the best possible treatment option for this individual. This technology has enabled the development of targeted therapies like Herceptin for metastatic breast cancer, Gleevec for chronic myeloid leukemia and Erbitux for metastatic colorectal cancer. |
[CML] A group of CMLHope.Com Subscribe: [EMAIL PROTECTED] Web Site: http://groups.cmlhope.com
